Daewoong, Almirall enter into licensing agreement for new COPD treatment

Daewoong Pharmaceutical said Thursday that it has signed an exclusive licensing agreement with Spain based Almirall S.A. for marketing Amirall’s Eklira (aclidinium bromide) in Korea.

Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently being developed as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

Preclinically, aclidinium showe...